The main known function of ApoC-III is to inhibit the activity of lipoprotein lipase, delaying the clearance of triglyceride-rich lipoproteins (VLDL and chylomicrons) and has been associated with increased risk of hypertriglyceridemia and poor CVD outcomes28,29. This evidence concerns the gene LPL and hypertriglyceridemia.